肾上腺皮质癌。
Adrenocortical carcinoma.
机构信息
MEND/Division of Metabolism, Endocrinology, and Diabetes (T.E., T.J.G., G.D.H.), Division of Molecular Medicine and Genetics (V.M.R.), Department of Internal Medicine; Departments of Radiation Oncology (A.S., J.S.), Pathology (T.J.G.), and Radiology (A.K., E.M.C.); and Division of Endocrine Surgery (B.S.M.), Section of General Surgery, (A.C.K.), Department of Surgery, University of Michigan Hospital and Health Systems, Ann Arbor, Michigan 48109.
出版信息
Endocr Rev. 2014 Apr;35(2):282-326. doi: 10.1210/er.2013-1029. Epub 2013 Dec 20.
Abstract
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy, often with an unfavorable prognosis. Here we summarize the knowledge about diagnosis, epidemiology, pathophysiology, and therapy of ACC. Over recent years, multidisciplinary clinics have formed and the first international treatment trials have been conducted. This review focuses on evidence gained from recent basic science and clinical research and provides perspectives from the experience of a large multidisciplinary clinic dedicated to the care of patients with ACC.
摘要
肾上腺皮质癌 (ACC) 是一种罕见的内分泌恶性肿瘤，通常预后不良。本文总结了 ACC 的诊断、流行病学、病理生理学和治疗方面的知识。近年来，多学科诊所已经形成，并开展了首次国际治疗试验。本综述重点关注了最近基础科学和临床研究中获得的证据，并从专门治疗 ACC 患者的大型多学科诊所的经验中提供了一些观点。
相似文献
1
Adrenocortical carcinoma.肾上腺皮质癌。
Endocr Rev. 2014 Apr;35(2):282-326. doi: 10.1210/er.2013-1029. Epub 2013 Dec 20.
2
[Treatment of adrenocortical carcinomas is challenging].肾上腺皮质癌的治疗具有挑战性。
Ugeskr Laeger. 2013 Apr 22;175(17):1181-5.
3
Treatment of adrenocortical carcinoma: contemporary outcomes.肾上腺皮质癌的治疗：当代治疗效果
Curr Urol Rep. 2004 Feb;5(1):65-72. doi: 10.1007/s11934-004-0014-x.
4
Adrenal cortical carcinoma.肾上腺皮质癌
World J Surg. 2001 Jul;25(7):914-26. doi: 10.1007/s00268-001-0030-7.
5
Recent advances in adrenocortical carcinoma in adults.成人肾上腺皮质癌的最新进展。
Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):192-7. doi: 10.1097/MED.0b013e3283602274.
6
[Adrenocortical carcinoma].[肾上腺皮质癌]
Nihon Rinsho. 2006 May 28;Suppl 1:720-3.
7
Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.肾上腺皮质癌的诊断与医学治疗的未来方向
Endocr Relat Cancer. 2016 Jan;23(1):R43-69. doi: 10.1530/ERC-15-0452. Epub 2015 Oct 16.
8
Management of adrenocortical carcinoma.肾上腺皮质癌的管理
J Natl Compr Canc Netw. 2009 Jul;7(7):752-8; quiz 759. doi: 10.6004/jnccn.2009.0051.
9
[Adrenocortical carcinoma].[肾上腺皮质癌]
Nihon Rinsho. 2001 Nov;59 Suppl 7:393-400.
10
Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment.肾上腺皮质癌的基因组和表达谱分析：在诊断、预后及治疗中的应用
Future Oncol. 2009 Jun;5(5):641-55. doi: 10.2217/fon.09.45.
引用本文的文献
1
Update on Medical Treatment of Cushing's Syndrome.库欣综合征的医学治疗进展
Drugs. 2025 Sep 15. doi: 10.1007/s40265-025-02223-8.
2
Educational Point-of-Care Ultrasound Discovers Adrenal Cortical Carcinoma, a Case Report: Clinical Implications and Review of the Literature.床旁超声教育发现肾上腺皮质癌：一例报告及文献复习的临床意义
HCA Healthc J Med. 2025 Aug 1;6(4):349-354. doi: 10.36518/2689-0216.1944. eCollection 2025.
3
Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials.全身治疗在转移性肾上腺皮质癌中的疗效：前瞻性临床试验的荟萃分析
Endocr Oncol. 2025 Sep 5;5(1):e250027. doi: 10.1530/EO-25-0027. eCollection 2025 Jan.
4
Feminizing Adrenal Tumour - A Case Series from a Tertiary Care Centre in Northern India.女性化肾上腺肿瘤——来自印度北部一家三级护理中心的病例系列
Indian J Endocrinol Metab. 2025 Jul-Aug;29(4):429-433. doi: 10.4103/ijem.ijem_9_25. Epub 2025 Aug 26.
5
Differentiating between adrenocortical carcinoma and pheochromocytoma by a CT-based radiomics model: a multicenter retrospective study.基于CT的影像组学模型鉴别肾上腺皮质癌和嗜铬细胞瘤：一项多中心回顾性研究
BMC Med Imaging. 2025 Aug 1;25(1):310. doi: 10.1186/s12880-025-01842-7.
6
Hyperandrogenism-induced Athletic Excellence in a Young Patient with Adrenocortical Carcinoma: 10 Years of Remission.肾上腺皮质癌年轻患者中高雄激素血症诱导的卓越运动能力：10年缓解期
JCEM Case Rep. 2025 Jul 31;3(9):luaf170. doi: 10.1210/jcemcr/luaf170. eCollection 2025 Sep.
7
Prognostic Factors Among Patients with Non-metastatic Adrenocortical Carcinoma.非转移性肾上腺皮质癌患者的预后因素
Int J Endocrinol Metab. 2025 Apr 30;23(2):e159772. doi: 10.5812/ijem-159772.
8
Prognostic factors and treatment outcomes in patients with adrenal cortical carcinoma: A registry-based study.肾上腺皮质癌患者的预后因素及治疗结果：一项基于登记处的研究。
Medicine (Baltimore). 2025 Jul 25;104(30):e42831. doi: 10.1097/MD.0000000000042831.
9
Recent advances on the role of G0S2.G0S2作用的最新进展
Discov Oncol. 2025 Jul 18;16(1):1362. doi: 10.1007/s12672-025-03198-4.
10
Adrenocortical carcinoma survival gene HMMR was identified as being targeted by fluorouracil and epirubicin using a gene coexpression network-based drug repositioning strategy.使用基于基因共表达网络的药物重新定位策略，肾上腺皮质癌生存基因HMMR被确定为氟尿嘧啶和表柔比星的作用靶点。
Sci Rep. 2025 Jul 17;15(1):25912. doi: 10.1038/s41598-025-10452-w.
本文引用的文献
1
Adrenocortical carcinoma is a lynch syndrome-associated cancer.肾上腺皮质癌是林奇综合征相关的癌症。
J Clin Oncol. 2013 Aug 20;31(24):3012-8. doi: 10.1200/JCO.2012.48.0988. Epub 2013 Jul 22.
2
Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.新生儿筛查和监测 TP53 R337H 突变对儿童肾上腺皮质肿瘤早期检测的影响。
J Clin Oncol. 2013 Jul 10;31(20):2619-26. doi: 10.1200/JCO.2012.46.3711. Epub 2013 Jun 3.
3
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.甲灭酸水平可预测接受根治性切除术辅助治疗后的肾上腺皮质癌患者的结局。
Eur J Endocrinol. 2013 Jul 29;169(3):263-70. doi: 10.1530/EJE-13-0242. Print 2013 Sep.
4
Adrenocortical cancer and IGF2: is the game over or our experimental models limited?肾上腺皮质癌与胰岛素样生长因子2：游戏结束了还是我们的实验模型存在局限性？
J Clin Endocrinol Metab. 2013 Feb;98(2):505-7. doi: 10.1210/jc.2012-3310. Epub 2013 Jan 7.
5
Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.患者在接受米托坦治疗的肾上腺皮质癌期间妊娠：病例报告及文献复习。
J Clin Endocrinol Metab. 2013 Feb;98(2):443-7. doi: 10.1210/jc.2012-2839. Epub 2012 Dec 28.
6
Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma.在一系列未经选择的肾上腺皮质癌患者的前瞻性研究中，胚系 TP53 突变的发生率。
J Clin Endocrinol Metab. 2013 Jan;98(1):E119-25. doi: 10.1210/jc.2012-2198. Epub 2012 Nov 21.
7
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.在肾上腺皮质癌中，米托坦治疗诱导 CYP3A4 并抑制 5α-还原酶，这解释了为什么需要个体化的糖皮质激素和雄激素替代治疗。
J Clin Endocrinol Metab. 2013 Jan;98(1):161-71. doi: 10.1210/jc.2012-2851. Epub 2012 Nov 16.
8
Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates.类固醇生成因子 1 在肾上腺皮质癌中的诊断和预后作用：一项侧重于临床和病理相关性的验证研究。
Hum Pathol. 2013 May;44(5):822-8. doi: 10.1016/j.humpath.2012.07.025. Epub 2012 Nov 14.
9
Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy.腹腔镜肾上腺切除术切除肾上腺皮质癌不如开放性肾上腺切除术彻底，局部复发更快、更常见。
Surgery. 2012 Dec;152(6):1150-7. doi: 10.1016/j.surg.2012.08.024.
10
The role of surgery in the management of recurrent adrenocortical carcinoma.手术在复发性肾上腺皮质癌治疗中的作用。
J Clin Endocrinol Metab. 2013 Jan;98(1):181-91. doi: 10.1210/jc.2012-2559. Epub 2012 Nov 12.
Zotero 插件